Premium
P3‐043: TARGETING THE EOTAXIN/CCR3 PATHWAY IN AGING‐ASSOCIATED COGNITIVE DECLINE
Author(s) -
Minami S. Sakura,
Rege Sanket,
Hackbart Hannah,
Czirr Eva,
Braithwaite Steven P.
Publication year - 2018
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2018.06.1398
Subject(s) - eotaxin , antagonist , ccr3 , cognitive decline , barnes maze , medicine , inflammation , dementia , population , immunology , chemokine , endocrinology , psychology , receptor , chemokine receptor , disease , hippocampus , spatial learning , environmental health
after treatment. Student t-test was used to compare the different groups of animals. Animals were visually and histologically inspected for tumor formation. Results: Treatment of eSCs and mSCs by a less-invasive intravenous route in the MPTP PD rodent model provided augmentation in motor abilities at early (10 days post-treatment) and later (3 months post-treatment) time points. Also, this treatment was deemed to be safe from teratomas. Conclusions: Motor impairment observed in MPTP-induced PD mice ameliorates after the treatment with NPs, and this is more evident several days after the therapy. Therefore, peripheral administration of NPs could be a promising therapy to treat motor impairment associated to PD.